不同剂量阿托伐他汀对老年高血压患者血脂水平及炎性因子的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (551 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influence of different doses atorvastatin on the serum lipid and high sensitive C-reactive protein ( hs-CRP ),IL-6,TNF-α in elderly patients with hypertension.Methods 120 elderly patients with hypertension were divided into three groups randomly: the control group,the atorvastatin treatment group 1 ( 10 mg/d) and the atorvastatin treatment group 2 ( 20 mg/d) . Each group received regular anti-hypertension treatment,the atorvastatin treatment groups were administered atrovastatin orally. Therapeutic time was 8 weeks. Blood pressure,TC,LDL-C,hs-CRP,IL-6,TNF-α contents were measured before and after therapy. Results Compared with before treatment, in the three groups after treatment, systolic blood pressure and diastolic blood pressure were significantly decreased (P<0.05). In the three groups of patients, TC, LDL-C, hs-CRP, IL-6 and TNF alpha all had varying degrees of decline, in treatment group 1 and group 2 decreased more significantly (P<0.05). TC in control group and treatment groups 1 and 2 were (5.89±0.53) mmol/L,(5.11±0.53) mmol/L and(4.92±0.23) mmol/L after treatment,respectively; LDL-C were(3.09±0.71) mmol/L,(2.69±0.33)mmol/L and(2.21±0.31) mmol/L; hs-CRP were(6.84±0.63) mg/L,(5.79±0.98 )mg/L and(4.49±1.01) mg/L. Compared with control group, in the two treatment groups, TC, LDL - C, hs CRP, IL 6 and TNF alpha significantly reduced, treatment 1 set of TC, LDL-C, hs-CRP significantly decreased (P<0.05). In treatment group 2, LCL-C and hs-CRP were significantly lower than in treatment group 1 (P< 0.05). Conclusions Atorvastatin can significantly reduce blood fat levels and inflammatory factor levels in the elderly patients with high blood pressure, and appropriate increase atorvastatin of dosage helps to improve curative effect, is worth promoting.

Key words： atorvastatin elderly patients hypertension high sensitive C-reactive protein IL-6 TNF-α

Received: 15 March 2015

ZTFLH:

R544.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Wei
	WEI Hongmei
	JIANG Aihua
	YANG Xixi
	ZHANG Tongle

Cite this article:

FANG Wei,WEI Hongmei,JIANG Aihua等. Effects of atorvastatin on serum lipid and hs-CRP,IL-6,TNF-α in elderly patients with hypertension[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(7): 693-695.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I7/693

[9]	许文亮,徐莉,王旭,等. 高血压患者平均血小板体积和血清高敏C反应蛋白水平的变化及相关关系[J]. 中华高血压杂志, 2011, 19 (11): 1080-1082.
[1]	苗青,杨菲. 阿托伐他汀对不稳定性心绞痛患者血清炎性因子水平的影响[J]. 血栓与止血学, 2012, 18(2): 66-68.
[10]	朱焕亮,陈练.血清hs-CRP、IL-6、TNF-A水平与不同程度高血压病的关系[J]. 放射免疫学杂志, 2011,24(2):220-221.
[2]	李华,白俊云,王红,等. 高血压联合降压治疗与动脉弹性的关系[J].中国循证心血管医学杂志, 2010, 2(4): 232-236.
[11]	张昌华.阿托伐他汀治疗老年高血压合并动脉粥样硬化的临床研究[J].当代医学,2012,18(32):129-130.
[3]	Kuklinska A M, Mroczko B. High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia [J]. Adv Med, 2009, 54(2): 225-232.
[4]	郭林娜,郭红. 阿托伐他汀对血脂正常高血压患者疗效观察[J]. 医药论坛杂志, 2011,32(7):156-157.
[5]	Charbonneau F, Anderson T J, Title L, et al. Modulation of arterial reactivity using amlodipine and atorvastat in measured by ultrasound examination[J]. Atherosclerosis, 2008, 197(1): 420 - 427.
[6]	李彦宏,葛鸿宇. 不同剂量阿伐他汀治疗急性冠状动脉综合征的临床观察[J]. 中国医药指南, 2011,9(21):310-311.
[7]	李娟,杨军,杨鸿羽,等. 高血压患者尿微量白蛋白与血浆高敏C反应蛋白的关系[J]. 心血管康复医学杂志, 2010, 19 (6) : 627-629.
[8]	Ridker P M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease [J]. Criculation, 2011, 103: 1813-818.
[9]	许文亮,徐莉,王旭,等. 高血压患者平均血小板体积和血清高敏C反应蛋白水平的变化及相关关系[J]. 中华高血压杂志, 2011, 19 (11): 1080-1082.
[10]	朱焕亮,陈练.血清hs-CRP、IL-6、TNF-A水平与不同程度高血压病的关系[J]. 放射免疫学杂志, 2011,24(2):220-221.
[11]	张昌华.阿托伐他汀治疗老年高血压合并动脉粥样硬化的临床研究[J].当代医学,2012,18(32):129-130.